NeuroSense Therapeutics ( NASDAQ: NRSN ) on Friday announced that it received a notice of delisting from Nasdaq. The staff of Nasdaq determined that the company's securities did not regain compliance with the minimum $2.5 million stockholders' equity requirement for continued listing.
The company stated that it intends to request a hearing before a panel, which would automatically stay any suspension or delisting action. Source: Press Release More on NeuroSense Therapeutics NeuroSense Therapeutics sheds 6% on $4.5M direct private offering Seeking Alpha’s Quant Rating on NeuroSense Therapeutics Historical earnings data for NeuroSense Therapeutics Financial information for NeuroSense Therapeutics.
